chikungunya

Valneva announced Wednesday that the U.S. FDA has granted its VLA1553 single-shot chikungunya vaccine candidate (currently in Phase 3) Breakthrough Therapy Designation—adding to the PRIority MEdicines (PRIME) designation the EMA awarded the French company’s jab in 2020 and the FDA Fast Track status it received in 2018.

Days after its CEO faced withering criticism from U.S. lawmakers over production mistakes with Covid-19 vaccines, Emergent BioSolutions had rosier news: two-year persistence data from a Phase 2 trial of the Maryland-based company’s chikungunya virus-like particle vaccine candidate (CHIKV-VLP) showed mean neutralizing antibody titers 19 times higher than pre-vaccination titers, according to a Wednesday press release.

Citing the lasting response to a single adjuvanted dose of the vaccine…

Vaccine makers Vaccitech and Valneva separately filed plans last week for initial public offerings on Nasdaq.

Oxford-based Vaccitech is the Jenner Institute spinout that owns the technology underlying the AstraZeneca/Oxford Covid-19 vaccine. Its pipeline includes a Phase 1 MERS vaccine and a preclinical zoster shot.

France’s Valneva, already listed on Euronext and proposing to list American depositary shares via a new offering, is seeking regulatory clearance to advance its…

France’s bioMérieux has secured European CE marking for three fully automated immunoassays for dengue, the company announced Wednesday.

Performed on the company’s Vidas family platforms, the Vidas Dengue NS1 Ag, Anti-Dengue IgM and Anti-Dengue IgG are “cost-effective and suitable for low- and middle-income countries,” according to the press release.

The company plans to add a chikungunya assay to its diagnostic offerings, per the announcement.

The Coalition for Epidemic Preparedness Innovations (CEPI) released a $3.5 billion investment case on Wednesday, outlining a five-year plan that includes a “moonshot” objective: compressing vaccine development timelines to 100 days.

Among the plan’s other goals are developing vaccines for known threats (such as chikungunya, Lassa fever and Nipah), producing a “library of prototype vaccines” from critical viral families, and supporting vaccine manufacturing in low- and middle-income…

Adjuvant Capital announced last week a $300 million Global Health Technology Fund focused on accelerating the development of medical innovations for “historically overlooked public health challenges.”

The New York-based social impact investor noted in its press release that it has already backed 14 companies, requiring each to make products broadly accessible to people in low- and middle-income countries. Adjuvant’s “young portfolio” includes investments in companies addressing…

Evotec has dosed the first participant in a Phase 1 study of EVT894, its monoclonal antibody (mAb) to treat and potentially prevent chikungunya infections, the company announced last week.

Sanofi initially developed the mAb and licensed it to Evotec as part of the 2018 transfer of Sanofi’s Lyon-based infectious disease R&D unit to the German company, according to the press release.

Bayer launched on Monday its Fludora Co-Max dual-action space spray solution for combating insecticide-resistant Aedes mosquito-borne arboviruses including chikungunya, dengue and Zika.

The spray combines two compounds (transfluthrin and flupyradifurone) and can be diluted with water to “maintain efficacy over greater distances” and reduce environmental impact, the press release said. Fludora Co-Max has been available in Côte d’Ivoire since November; Bayer will introduce it in other…

Takeda CEO Christophe Weber told Reuters in an interview last week that vaccines could join gastroenterology, neuroscience, oncology, plasma-derived therapies and rare diseases as a sixth “key business” for the Japanese drugmaker.

Takeda currently has a quadrivalent dengue shot (TAK-003) in Phase 3, a norovirus vaccine in Phase 2, a Zika candidate in Phase 1 and a chikungunya shot in preclinical.

The company has also struck deals to produce 250 million doses of Novavax’s Covid-19…

Valneva announced Friday that the European Medicines Agency has granted its VLA1553 chikungunya vaccine candidate (now in Phase 3) a PRIority MEdicines (PRIME) designation. The U.S. FDA granted the shot Fast Track status in 2018.

In a separate announcement, the French biotech touted initial results Tuesday showing that its VLA15 Lyme disease vaccine candidate—co-developed with Pfizer—has met Phase 2 endpoints. The shot was well-tolerated, seroconversion rates exceeded 90%, and…